ANTECH
Antech, the veterinary diagnostics company focused on partnering with veterinary professionals to predict, diagnose, and monitor wellness and disease, today announced the launch of the breakthrough in-hospital Nu.Q® Canine Cancer Test in Europe. A rapid, accurate, targeted cancer screening tool for high-risk breeds and older dogs, Nu.Q® testing also includes prevalent types of canine cancers, enabling veterinarians and pet owners to make informed decisions about cancer care more quickly.
Jimmy Barr, DVM, DACVECC, Chief Medical Officer at Antech, part of Mars Science & Diagnostics said: “It’s exciting to see innovations like Nu.Q® Canine Cancer Test become more widely available to veterinary teams in Europe. With cancer affecting one in four dogs1, it is critical that veterinary professionals have access to fast and accurate cancer screening methods, so they can make informed and timely decisions and ultimately change pet health outcomes. This is what our work at Antech is all about.”
Nu.Q® Canine Cancer Test is a breakthrough technology that measures circulating nucleosomes, supporting earlier cancer detection in some of the most prevalent types of canine cancers. Nu.Q® testing, run on the Element i+ analyser, is both cost-effective and simple, requiring only 50µL of EDTA plasma from a patient and providing accurate results in 5 to 10 minutes. Studies2 have shown >75% detection rates for common cancers in dogs like lymphoma and hemangiosarcoma when using Nu.Q®. As the only patient-side in-house test that provides rapid and accurate results from EDTA plasma, the Nu.Q® test is an aid to diagnosis that can be run in clinic by veterinary professionals during annual check-ups or regular senior wellness exams.
Dr. Maximiljan W. Krauss, Dipl. ECVS, Tierklink Düsseldorf, used Nu.Q® Canine Cancer Test first-hand during the pilot phase and commented: “At our clinic, we see around 1500 cases of cancer in dogs a year. Lymphoma and hemangiosarcoma are the most common type of cancer we see affecting dogs as young as five years old. Thanks to Nu.Q® Canine Cancer Test and the Element i+ in-house analyzer, we have a fast and accurate means to screen for cancer, which helps us intervene early and choose the best possible care pathway for every patient. At the end of the day, early interventions can make a real difference to a dog’s quality of life and the time they have to spend with their family.”
Nu.Q® is a registered trademark of VolitionRx Limited and its subsidiaries. The Nu.Q® Canine Cancer Test is supplied under license by Belgian Volition SRL.
Nu.Q® will be available in the UK as part of the European launch. For orders and more information about the product, please contact Antech UK.
About Mars Science & Diagnostics and Antech
Mars Science & Diagnostics is a division of Mars Petcare, a diverse business dedicated to one purpose: A BETTER WORLD FOR PETS™. Science & Diagnostics brings together the power of leading pet health science with expertise across diagnostics, data, and technology to improve outcomes in pet health. Our veterinary diagnostics business, Antech, spans in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software and related software and support; 90+ reference laboratories around the globe; veterinary imaging and technology; education; and board-certified specialist support services. Our at-home diagnostics offering includes Wisdom Panel™ DNA test products, the world’s most accurate pet DNA test. For 60 years, our Waltham Petcare Science Institute has been advancing science to better understand pet health.
2 Wilson-Robles, H.M., Bygott, T., Kelly, T.K. et al. Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Vet Res 18, 329 (2022). https://doi.org/10.1186/s12917-022-03429-8
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422725707/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LambdaTest Elevates Mudit Singh to Co-Founder as the Company Accelerates Its Next Phase of Growth4.12.2025 17:00:00 CET | Press release
Strengthening leadership as LambdaTest accelerates its next phase of AI-powered testing innovation and enterprise growth LambdaTest, a leading GenAI-native quality engineering platform, today announced the promotion of Mudit Singh to Co-Founder. This move recognizes his contributions in shaping the company's growth, strengthening its global brand, and driving product adoption across key markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204685161/en/ Mudit Singh, Co-Founder and Head of Growth, LambdaTest Mudit joined LambdaTest in 2017 and has been instrumental in building the company's marketing engine, product-led growth initiatives, and community programs. Under his leadership as Head of Marketing and Growth, LambdaTest expanded its enterprise footprint, launched high-impact campaigns, and became a trusted partner for thousands of development and QA teams worldwide. "Mudit has been part of LambdaTest's story since
Rigaku Launches XTRAIA MF-3400, a Measuring Instrument for Next-generation Semiconductors4.12.2025 16:00:00 CET | Press release
High-precision wafer measurement meets surging demand from AI and data centers Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) has launched the XTRAIA MF-3400, an instrument used in semiconductor manufacturing processes to measure the thickness and composition of wafers. The XTRAIA MF-3400 will significantly enhance productivity in the rapidly growing semiconductor market by enabling high-accuracy evaluation of materials essential for mass production of next-generation memory chips and high-speed AI devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204537975/en/ XTRAIA MF-3400 As generative AI and data centers continue to expand, demand is rising for high-performance, energy-efficient semiconductors capable of processing vast volumes of data. Consequently, semiconducto
Energy Vault Secures Swiss Market Entry with Signed B-VAULT™ Deployment Contracts for Schindler and Energie Wettingen Projects, Launch of FlexGrid Product for Urban and Utility Applications4.12.2025 15:20:00 CET | Press release
Energy Vault signs two B-VAULT™ contracts in the Swiss market for projects with Schindler Aufzüge AG and Energie Wettingen, marking the launch of Energy Vault’s B-Vault™ FlexGrid program designed for commercial and industrial (C&I) customersSwitzerland is a cornerstone of Energy Vault’s European strategy, with the company moving decisively to expand its presence with multiple projects per year as part of a broader European growth strategyIntegration with CKW’s Flexpool flexibility market set to enable participation in frequency regulation, voltage control, and reactive power marketsThe Schindler FlexGrid-enabled B-VAULT system is operating and qualified by Swissgrid Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault" or the "Company"), a global leader in grid-scale energy storage solutions, today announced its formal entry into the Swiss market with the launch of FlexGrid, a product designed for C&I customers based on a new configuration of its B-VAULT battery energy storage syste
MSCI Launches Breakthrough Index Integrating Public Markets and Private Equity4.12.2025 15:00:00 CET | Press release
Innovative index is designed to provide a broad and daily view of the global equity opportunity MSCI Inc. (NYSE: MSCI) launched the MSCI All Country Public + Private Equity Index,an innovative daily index that combines public markets and a broad private equity view within a single, coherent framework. The launch marks a major shift in how investors can assess total equity exposures and measure performance across their portfolio. With private markets increasingly integrated into investment portfolios, private equity is becoming a core component of total portfolio allocation, contributing to diversification, long-term return potential and exposure to segments of the economy not captured by public markets. Reflecting the evolving structure of investor portfolios, this index sets a new standard for tracking global equity performance across public and private markets. The index combines the flagship MSCI ACWI IMI, which represents the performance of the full opportunity set of publicly list
University of Maryland Launches Innovative Clinician Training Program in Ketogenic Metabolic Therapy for Mental Health4.12.2025 15:00:00 CET | Press release
Funding from Baszucki Group fuels program for healthcare professionals to learn by doing. Baszucki Group today announced a partnership with University of Maryland School of Medicine for an innovative training initiative that will build capacity for delivering ketogenic metabolic therapy in mental health care. The program, titled “LIVE IT~LAUNCH IT: Learning How to Implement and Use a Ketogenic Diet to Improve Mental Health in Your Patients For Health Care Workers” is led by Deanna Kelly, PharmD, BCPP, the Dr. William and Carol Carpenter Professor in Psychiatry for Mental Illness Research and Director of the Maryland Psychiatric Research Center at the University of Maryland School of Medicine. This initiative aims to educate and empower practitioners by guiding them in adopting the intervention themselves. The aim is to prepare a variety of healthcare professionals to safely and confidently incorporate this promising personalized metabolic treatment framework in both clinical and resear
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom